Skip to main content
. 2021 Nov 9;95(23):e02379-20. doi: 10.1128/JVI.02379-20

FIG 4.

FIG 4

Competitive HAI assay using H1N1-specific mouse MAbs against seasonal and pandemic H1N1 virus strains. (A to D) HAI fold reduction of MAb AT163.210.182 (A), MAb 5B-2A12 (B), or a 1:1 combination of MAb AT163.210.182 and MAb 5B-2A12 (C and D) against H1N1 seasonal (NC/99) and pandemic (CA/09) influenza virus strains following preabsorption with rHAΔSA protein representing homologous seasonal (NC/99) or pandemic (CA/09) virus strains. Differences in HAI titer were analyzed using a t test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001). Dotted line represents the 4-fold change in the HAI titer.